Abstract
Background: One-third of cervical cancer patients are still diagnosed at advanced stages. The five-year survival rate is decreased in about 50% of advanced stage cervical cancer patients worldwide, and the clinical outcomes are remarkably varied and difficult to predict. One of the miRNAs known to be associated with cancer tumorigenesis is miR-944. However, the prognostic value of miR-944 in cervical cancer has not been fully investigated. The aim of this study was to analyze clinical significance and prognostic value of miR-944 in cervical cancer. Methods: The expression levels of miR-944 were detected using quantitative reverse transcription polymerase chain reaction in five types of cervical cancer cell lines and 116 formalin-fixed paraffin-embedded (FFPE) cervical tissues. The association between the expression levels of miR-944 and prognostic value was analyzed using the Kaplan-Meier analysis and Cox proportional hazards model. Results: The expression levels of miR-944 in cervical cancer tissues were significantly higher compared with those in normal tissues (P < 0.0001). Moreover, the expression levels of miR-944 in cervical cancer cell lines and FFPE tissues with human papillomavirus (HPV) infection were significantly higher compared to those without HPV infection (P < 0.01 and P = 0.02). High miR-944 expression was also markedly associated with bulky tumor size (P = 0.026), advanced International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.042), and lymph node metastasis (P = 0.030). In particular, high miR-944 expression group showed shorter overall survival than the low miR-944 expression group in the advanced FIGO stage (84.4% vs. 44.4%, HR = 4.0, and P = 0.01). Conclusions: These results suggest that miR-944 may be used as a novel biomarker for improving prognosis and as a potential therapeutic target.
| Original language | English |
|---|---|
| Article number | 419 |
| Journal | BMC cancer |
| Volume | 19 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2019 May 6 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Genetics
- Oncology
- Cancer Research
Cite this
}
MicroRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer. / Park, Sunyoung; Kim, Jungho; Eom, Kiyoon; Oh, Sehee; Kim, Sunghyun; Kim, Geehyuk; Ahn, Sungwoo; Park, Kwang Hwa; Chung, Dawn; Lee, Hyeyoung.
In: BMC cancer, Vol. 19, No. 1, 419, 06.05.2019.Research output: Contribution to journal › Article
TY - JOUR
T1 - MicroRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer
AU - Park, Sunyoung
AU - Kim, Jungho
AU - Eom, Kiyoon
AU - Oh, Sehee
AU - Kim, Sunghyun
AU - Kim, Geehyuk
AU - Ahn, Sungwoo
AU - Park, Kwang Hwa
AU - Chung, Dawn
AU - Lee, Hyeyoung
PY - 2019/5/6
Y1 - 2019/5/6
N2 - Background: One-third of cervical cancer patients are still diagnosed at advanced stages. The five-year survival rate is decreased in about 50% of advanced stage cervical cancer patients worldwide, and the clinical outcomes are remarkably varied and difficult to predict. One of the miRNAs known to be associated with cancer tumorigenesis is miR-944. However, the prognostic value of miR-944 in cervical cancer has not been fully investigated. The aim of this study was to analyze clinical significance and prognostic value of miR-944 in cervical cancer. Methods: The expression levels of miR-944 were detected using quantitative reverse transcription polymerase chain reaction in five types of cervical cancer cell lines and 116 formalin-fixed paraffin-embedded (FFPE) cervical tissues. The association between the expression levels of miR-944 and prognostic value was analyzed using the Kaplan-Meier analysis and Cox proportional hazards model. Results: The expression levels of miR-944 in cervical cancer tissues were significantly higher compared with those in normal tissues (P < 0.0001). Moreover, the expression levels of miR-944 in cervical cancer cell lines and FFPE tissues with human papillomavirus (HPV) infection were significantly higher compared to those without HPV infection (P < 0.01 and P = 0.02). High miR-944 expression was also markedly associated with bulky tumor size (P = 0.026), advanced International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.042), and lymph node metastasis (P = 0.030). In particular, high miR-944 expression group showed shorter overall survival than the low miR-944 expression group in the advanced FIGO stage (84.4% vs. 44.4%, HR = 4.0, and P = 0.01). Conclusions: These results suggest that miR-944 may be used as a novel biomarker for improving prognosis and as a potential therapeutic target.
AB - Background: One-third of cervical cancer patients are still diagnosed at advanced stages. The five-year survival rate is decreased in about 50% of advanced stage cervical cancer patients worldwide, and the clinical outcomes are remarkably varied and difficult to predict. One of the miRNAs known to be associated with cancer tumorigenesis is miR-944. However, the prognostic value of miR-944 in cervical cancer has not been fully investigated. The aim of this study was to analyze clinical significance and prognostic value of miR-944 in cervical cancer. Methods: The expression levels of miR-944 were detected using quantitative reverse transcription polymerase chain reaction in five types of cervical cancer cell lines and 116 formalin-fixed paraffin-embedded (FFPE) cervical tissues. The association between the expression levels of miR-944 and prognostic value was analyzed using the Kaplan-Meier analysis and Cox proportional hazards model. Results: The expression levels of miR-944 in cervical cancer tissues were significantly higher compared with those in normal tissues (P < 0.0001). Moreover, the expression levels of miR-944 in cervical cancer cell lines and FFPE tissues with human papillomavirus (HPV) infection were significantly higher compared to those without HPV infection (P < 0.01 and P = 0.02). High miR-944 expression was also markedly associated with bulky tumor size (P = 0.026), advanced International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.042), and lymph node metastasis (P = 0.030). In particular, high miR-944 expression group showed shorter overall survival than the low miR-944 expression group in the advanced FIGO stage (84.4% vs. 44.4%, HR = 4.0, and P = 0.01). Conclusions: These results suggest that miR-944 may be used as a novel biomarker for improving prognosis and as a potential therapeutic target.
UR - http://www.scopus.com/inward/record.url?scp=85065650488&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065650488&partnerID=8YFLogxK
U2 - 10.1186/s12885-019-5620-6
DO - 10.1186/s12885-019-5620-6
M3 - Article
C2 - 31060525
AN - SCOPUS:85065650488
VL - 19
JO - BMC Cancer
JF - BMC Cancer
SN - 1471-2407
IS - 1
M1 - 419
ER -